31 studies found for:    triple negative breast cancer | Phase 3, 4
Show Display Options
Rank Status Study
1 Active, not recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Recruiting PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
Conditions: Breast Cancer;   Brain Metastasis
Intervention: Radiation: prophylactic cranial irradiation
3 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
4 Recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
5 Recruiting Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fu/epirubicin/CTX following Docetaxel;   Drug: Docetaxel/capecitabine followed by XEC
6 Not yet recruiting A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin
7 Recruiting Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention:
8 Not yet recruiting Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Condition: Breast Cancer
Interventions: Drug: taxane plus carboplatin;   Drug: Taxane
9 Completed Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
10 Completed
Has Results
BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin];   Drug: Standard adjuvant chemotherapy
11 Recruiting Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Capecitabine
12 Recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
13 Unknown  The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
Condition: Breast Cancer
Intervention: Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
14 Not yet recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
15 Completed A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: bevacizumab [Avastin]
16 Recruiting Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin and Paclitaxel;   Drug: Doxorubicin, cyclophosphamide;   Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
17 Active, not recruiting Triple Negative Breast Cancer Trial
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel
18 Recruiting MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
19 Active, not recruiting A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Ixabepilone (Ixempra);   Drug: Paclitaxel (Taxol)
20 Active, not recruiting Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Conditions: HER2-Negative Breast Cancer;   Triple Negative Breast Cancer;   Breast Cancer;   Cancer of Breast;   Breast Tumors
Interventions: Drug: E7389 (Eribulin Mesylate);   Drug: Vinorelbine injection

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years